A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

NCT01287039 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

489

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Asthma

Interventions

DRUG: Reslizumab
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.